HEADER COMPLEX (SERINE PROTEASE/COAGULATION) 30-AUG-96 1UCY TITLE THROMBIN COMPLEXED WITH FIBRINOPEPTIDE A ALPHA (RESIDUES 7-19). THREE TITLE 2 COMPLEXES, ONE WITH EPSILON-THROMBIN AND TWO WITH ALPHA-THROMBIN COMPND MOL_ID: 1; COMPND 2 MOLECULE: THROMBIN; COMPND 3 CHAIN: L, J, M; COMPND 4 EC: 3.4.21.5; COMPND 5 OTHER_DETAILS: CHYMOTRYPSINOGEN NUMBERING (RATHER THAN SEQUENTIAL) COMPND 6 SYSTEM IS USED, BASED ON THE TOPOLOGICAL ALIGNMENT WITH THE STRUCTURE COMPND 7 OF CHYMOTRYPSINOGEN (H.BRANDSTETTER ET AL., 1992, J.MOL.BIOL., V. COMPND 8 226, 1085). THE N-TERMINUS OF THE FIBRINOPEPTIDE IS ACETYLATED. COMPND 9 FIBRINOPEPTIDE SEQUENCE NUMBERS ARE ACE 6 TO ARG 19. A NEW RESIDUE, COMPND 10 OPR, HAS BEEN DEFINED FOR THE ARG/GLY COMBINATION IN WHICH THE AMIDE COMPND 11 NITROGEN HAS BEEN REPLACED WITH A CH2, MAKING THE NORMAL AMIDE BOND COMPND 12 BETWEEN THESE TWO RESIDUES A KETONE BOND. THE FIBRINOPEPTIDE COMPND 13 NUMBERING IS CONSEQUENTLY INCREMENTED BY 1 AFTER THIS RESIDUE IN COMPND 14 KEEPING WITH THE FIBRINOGEN NUMBERING SCHEME. THERE ARE ALTERNATE COMPND 15 CONFORMATIONS FOR RESIDUES PRO 18 AND ARG 19 IN FIBRINOPEPTIDE III.; COMPND 16 MOL_ID: 2; COMPND 17 MOLECULE: THROMBIN; COMPND 18 CHAIN: H; COMPND 19 EC: 3.4.21.5; COMPND 20 OTHER_DETAILS: CHYMOTRYPSINOGEN NUMBERING (RATHER THAN SEQUENTIAL) COMPND 21 SYSTEM IS USED, BASED ON THE TOPOLOGICAL ALIGNMENT WITH THE STRUCTURE COMPND 22 OF CHYMOTRYPSINOGEN (H.BRANDSTETTER ET AL., 1992, J.MOL.BIOL., V. COMPND 23 226, 1085). THE N-TERMINUS OF THE FIBRINOPEPTIDE IS ACETYLATED. COMPND 24 FIBRINOPEPTIDE SEQUENCE NUMBERS ARE ACE 6 TO ARG 19. A NEW RESIDUE, COMPND 25 OPR, HAS BEEN DEFINED FOR THE ARG/GLY COMBINATION IN WHICH THE AMIDE COMPND 26 NITROGEN HAS BEEN REPLACED WITH A CH2, MAKING THE NORMAL AMIDE BOND COMPND 27 BETWEEN THESE TWO RESIDUES A KETONE BOND. THE FIBRINOPEPTIDE COMPND 28 NUMBERING IS CONSEQUENTLY INCREMENTED BY 1 AFTER THIS RESIDUE IN COMPND 29 KEEPING WITH THE FIBRINOGEN NUMBERING SCHEME. THERE ARE ALTERNATE COMPND 30 CONFORMATIONS FOR RESIDUES PRO 18 AND ARG 19 IN FIBRINOPEPTIDE III.; COMPND 31 MOL_ID: 3; COMPND 32 MOLECULE: THROMBIN; COMPND 33 CHAIN: E; COMPND 34 EC: 3.4.21.5; COMPND 35 OTHER_DETAILS: CHYMOTRYPSINOGEN NUMBERING (RATHER THAN SEQUENTIAL) COMPND 36 SYSTEM IS USED, BASED ON THE TOPOLOGICAL ALIGNMENT WITH THE STRUCTURE COMPND 37 OF CHYMOTRYPSINOGEN (H.BRANDSTETTER ET AL., 1992, J.MOL.BIOL., V. COMPND 38 226, 1085). THE N-TERMINUS OF THE FIBRINOPEPTIDE IS ACETYLATED. COMPND 39 FIBRINOPEPTIDE SEQUENCE NUMBERS ARE ACE 6 TO ARG 19. A NEW RESIDUE, COMPND 40 OPR, HAS BEEN DEFINED FOR THE ARG/GLY COMBINATION IN WHICH THE AMIDE COMPND 41 NITROGEN HAS BEEN REPLACED WITH A CH2, MAKING THE NORMAL AMIDE BOND COMPND 42 BETWEEN THESE TWO RESIDUES A KETONE BOND. THE FIBRINOPEPTIDE COMPND 43 NUMBERING IS CONSEQUENTLY INCREMENTED BY 1 AFTER THIS RESIDUE IN COMPND 44 KEEPING WITH THE FIBRINOGEN NUMBERING SCHEME. THERE ARE ALTERNATE COMPND 45 CONFORMATIONS FOR RESIDUES PRO 18 AND ARG 19 IN FIBRINOPEPTIDE III.; COMPND 46 MOL_ID: 4; COMPND 47 MOLECULE: FIBRINOPEPTIDE A-ALPHA; COMPND 48 CHAIN: F, G, I; COMPND 49 FRAGMENT: RESIDUES 7 - 19; COMPND 50 ENGINEERED: YES; COMPND 51 OTHER_DETAILS: THREE COMPLEXES ARE PRESENTED, ONE WITH EPSILON- COMPND 52 THROMBIN AND TWO WITH ALPHA-THROMBIN; COMPND 53 MOL_ID: 5; COMPND 54 MOLECULE: THROMBIN; COMPND 55 CHAIN: K, N; COMPND 56 EC: 3.4.21.5 SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: BOS TAURUS; SOURCE 3 ORGANISM_COMMON: CATTLE; SOURCE 4 ORGANISM_TAXID: 9913; SOURCE 5 TISSUE: BLOOD; SOURCE 6 MOL_ID: 2; SOURCE 7 ORGANISM_SCIENTIFIC: BOS TAURUS; SOURCE 8 ORGANISM_COMMON: CATTLE; SOURCE 9 ORGANISM_TAXID: 9913; SOURCE 10 TISSUE: BLOOD; SOURCE 11 MOL_ID: 3; SOURCE 12 ORGANISM_SCIENTIFIC: BOS TAURUS; SOURCE 13 ORGANISM_COMMON: CATTLE; SOURCE 14 ORGANISM_TAXID: 9913; SOURCE 15 TISSUE: BLOOD; SOURCE 16 MOL_ID: 4; SOURCE 17 MOL_ID: 5; SOURCE 18 ORGANISM_SCIENTIFIC: BOS TAURUS; SOURCE 19 ORGANISM_COMMON: CATTLE; SOURCE 20 ORGANISM_TAXID: 9913; SOURCE 21 TISSUE: BLOOD KEYWDS COMPLEX (SERINE PROTEASE-COAGULATION), SERINE, PROTEASE, THROMBIN, KEYWDS 2 COMPLEX (SERINE PROTEASE-COAGULATION) COMPLEX EXPDTA X-RAY DIFFRACTION AUTHOR P.MARTIN,B.EDWARDS REVDAT 4 15-NOV-23 1UCY 1 SEQADV LINK ATOM REVDAT 3 24-FEB-09 1UCY 1 VERSN REVDAT 2 01-APR-03 1UCY 1 JRNL REVDAT 1 12-FEB-97 1UCY 0 JRNL AUTH P.D.MARTIN,M.G.MALKOWSKI,J.DIMAIO,Y.KONISHI,F.NI,B.F.EDWARDS JRNL TITL BOVINE THROMBIN COMPLEXED WITH AN UNCLEAVABLE ANALOG OF JRNL TITL 2 RESIDUES 7-19 OF FIBRINOGEN A ALPHA: GEOMETRY OF THE JRNL TITL 3 CATALYTIC TRIAD AND INTERACTIONS OF THE P1', P2', AND P3' JRNL TITL 4 SUBSTRATE RESIDUES. JRNL REF BIOCHEMISTRY V. 35 13030 1996 JRNL REFN ISSN 0006-2960 JRNL PMID 8855938 JRNL DOI 10.1021/BI960656Y REMARK 2 REMARK 2 RESOLUTION. 2.20 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : X-PLOR REMARK 3 AUTHORS : BRUNGER REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 2.20 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 7.00 REMARK 3 DATA CUTOFF (SIGMA(F)) : 1.000 REMARK 3 DATA CUTOFF HIGH (ABS(F)) : NULL REMARK 3 DATA CUTOFF LOW (ABS(F)) : NULL REMARK 3 COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 NUMBER OF REFLECTIONS : NULL REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : NULL REMARK 3 FREE R VALUE TEST SET SELECTION : NULL REMARK 3 R VALUE (WORKING SET) : 0.171 REMARK 3 FREE R VALUE : NULL REMARK 3 FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF FREE R VALUE : NULL REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : NULL REMARK 3 BIN RESOLUTION RANGE HIGH (A) : NULL REMARK 3 BIN RESOLUTION RANGE LOW (A) : NULL REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : NULL REMARK 3 REFLECTIONS IN BIN (WORKING SET) : NULL REMARK 3 BIN R VALUE (WORKING SET) : NULL REMARK 3 BIN FREE R VALUE : NULL REMARK 3 BIN FREE R VALUE TEST SET SIZE (%) : NULL REMARK 3 BIN FREE R VALUE TEST SET COUNT : NULL REMARK 3 ESTIMATED ERROR OF BIN FREE R VALUE : NULL REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 7432 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 0 REMARK 3 SOLVENT ATOMS : 733 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : NULL REMARK 3 MEAN B VALUE (OVERALL, A**2) : NULL REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : NULL REMARK 3 B22 (A**2) : NULL REMARK 3 B33 (A**2) : NULL REMARK 3 B12 (A**2) : NULL REMARK 3 B13 (A**2) : NULL REMARK 3 B23 (A**2) : NULL REMARK 3 REMARK 3 ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM LUZZATI PLOT (A) : 0.25 REMARK 3 ESD FROM SIGMAA (A) : 0.29 REMARK 3 LOW RESOLUTION CUTOFF (A) : NULL REMARK 3 REMARK 3 CROSS-VALIDATED ESTIMATED COORDINATE ERROR. REMARK 3 ESD FROM C-V LUZZATI PLOT (A) : NULL REMARK 3 ESD FROM C-V SIGMAA (A) : NULL REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES. REMARK 3 BOND LENGTHS (A) : 0.011 REMARK 3 BOND ANGLES (DEGREES) : 1.900 REMARK 3 DIHEDRAL ANGLES (DEGREES) : 19.40 REMARK 3 IMPROPER ANGLES (DEGREES) : 1.800 REMARK 3 REMARK 3 ISOTROPIC THERMAL MODEL : NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. RMS SIGMA REMARK 3 MAIN-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN BOND (A**2) : NULL ; NULL REMARK 3 SIDE-CHAIN ANGLE (A**2) : NULL ; NULL REMARK 3 REMARK 3 NCS MODEL : NULL REMARK 3 REMARK 3 NCS RESTRAINTS. RMS SIGMA/WEIGHT REMARK 3 GROUP 1 POSITIONAL (A) : NULL ; NULL REMARK 3 GROUP 1 B-FACTOR (A**2) : NULL ; NULL REMARK 3 REMARK 3 PARAMETER FILE 1 : NULL REMARK 3 TOPOLOGY FILE 1 : NULL REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: REMARK 3 THERE ARE THREE INDEPENDENT COMPLEXES IN THE ASYMMETRIC REMARK 3 UNIT. COMPLEX I IS EPSILON THROMBIN (ADDITIONAL CHAIN REMARK 3 BREAK BETWEEN RESIDUES 149A AND 149B), AND MOLECULES II AND REMARK 3 III ARE ALPHA THROMBIN. FIBRINOPEPTIDES I AND II HAVE REMARK 3 OCCUPANCIES THAT MAKES THE AVERAGE SIDE CHAIN B OF OPR-16 REMARK 3 ROUGHLY EQUAL TO THAT IN FIBRINOPEPTIDE III. THE REMARK 3 DEPOSITORS DO NOT SEE ANY DENSITY AT ALL FOR THROMBIN REMARK 3 RESIDUES 1U - 1I, AND POOR DENSITY FOR THE N AND C TERMINI REMARK 3 OF THE LIGHT CHAINS, THE C TERMINUS OF THE HEAVY CHAINS, REMARK 3 AND THE FIVE RESIDUES BORDERING 149B IN MOLECULES II AND REMARK 3 III. REMARK 4 REMARK 4 1UCY COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY BNL. REMARK 100 THE DEPOSITION ID IS D_1000176915. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : NULL REMARK 200 TEMPERATURE (KELVIN) : NULL REMARK 200 PH : NULL REMARK 200 NUMBER OF CRYSTALS USED : NULL REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : N REMARK 200 RADIATION SOURCE : NULL REMARK 200 BEAMLINE : NULL REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : NULL REMARK 200 WAVELENGTH OR RANGE (A) : NULL REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : X1000 MULTIWIRE REMARK 200 DETECTOR MANUFACTURER : SIEMENS REMARK 200 INTENSITY-INTEGRATION SOFTWARE : XENGEN REMARK 200 DATA SCALING SOFTWARE : XENGEN REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 45875 REMARK 200 RESOLUTION RANGE HIGH (A) : 2.200 REMARK 200 RESOLUTION RANGE LOW (A) : 7.000 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 1.000 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : NULL REMARK 200 DATA REDUNDANCY : NULL REMARK 200 R MERGE (I) : NULL REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : NULL REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 2.20 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 2.30 REMARK 200 COMPLETENESS FOR SHELL (%) : 15.0 REMARK 200 DATA REDUNDANCY IN SHELL : NULL REMARK 200 R MERGE FOR SHELL (I) : NULL REMARK 200 R SYM FOR SHELL (I) : 0.07200 REMARK 200 FOR SHELL : NULL REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: NULL REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: NULL REMARK 200 SOFTWARE USED: NULL REMARK 200 STARTING MODEL: NULL REMARK 200 REMARK 200 REMARK: NULL REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 60.73 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 3.13 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: P 1 21 1 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,Y+1/2,-Z REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 1.000000 0.000000 44.39000 REMARK 290 SMTRY3 2 0.000000 0.000000 -1.000000 0.00000 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1, 2, 3 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TETRAMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TETRAMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 12000 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13120 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -52.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: L, H, E, F REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 2 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4750 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13070 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -17.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: J, K, G REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 REMARK 350 BIOMOLECULE: 3 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: TRIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: TRIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 4840 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 13440 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -14.0 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: M, N, I REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 THR L 1U REMARK 465 SER L 1T REMARK 465 GLU L 1S REMARK 465 ASP L 1R REMARK 465 HIS L 1Q REMARK 465 PHE L 1P REMARK 465 GLN L 1O REMARK 465 PRO L 1N REMARK 465 PHE L 1M REMARK 465 PHE L 1L REMARK 465 ASN L 1K REMARK 465 GLU L 1J REMARK 465 LYS L 1I REMARK 465 THR J 1U REMARK 465 SER J 1T REMARK 465 GLU J 1S REMARK 465 ASP J 1R REMARK 465 HIS J 1Q REMARK 465 PHE J 1P REMARK 465 GLN J 1O REMARK 465 PRO J 1N REMARK 465 PHE J 1M REMARK 465 PHE J 1L REMARK 465 ASN J 1K REMARK 465 GLU J 1J REMARK 465 LYS J 1I REMARK 465 ARG G 19 REMARK 465 THR M 1U REMARK 465 SER M 1T REMARK 465 GLU M 1S REMARK 465 ASP M 1R REMARK 465 HIS M 1Q REMARK 465 PHE M 1P REMARK 465 GLN M 1O REMARK 465 PRO M 1N REMARK 465 PHE M 1M REMARK 465 PHE M 1L REMARK 465 ASN M 1K REMARK 465 GLU M 1J REMARK 465 LYS M 1I REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LEU H 40 CA - CB - CG ANGL. DEV. = 15.8 DEGREES REMARK 500 OPR F 16 CA - C - N ANGL. DEV. = 45.5 DEGREES REMARK 500 OPR G 16 CA - C - N ANGL. DEV. = 22.2 DEGREES REMARK 500 PRO G 18 C - N - CA ANGL. DEV. = 12.3 DEGREES REMARK 500 GLY M 14M N - CA - C ANGL. DEV. = 15.9 DEGREES REMARK 500 OPR I 16 CA - C - N ANGL. DEV. = 42.8 DEGREES REMARK 500 OPR I 16 CA - C - N ANGL. DEV. = 38.7 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 PHE L 1G 95.38 -46.68 REMARK 500 ALA L 1B -18.05 76.68 REMARK 500 PHE L 7 -87.60 -127.58 REMARK 500 TYR L 14J -91.24 -82.58 REMARK 500 ILE L 14K -95.70 49.96 REMARK 500 GLU L 14L 20.85 -167.76 REMARK 500 CYS H 42 -177.86 -170.69 REMARK 500 SER H 48 177.51 174.61 REMARK 500 TYR H 60A 79.84 -151.88 REMARK 500 HIS H 71 -57.13 -121.98 REMARK 500 ARG H 77A -82.76 -30.45 REMARK 500 ASN H 98 2.15 -150.46 REMARK 500 SER H 115 -167.28 -164.35 REMARK 500 THR H 149 -168.12 -127.05 REMARK 500 VAL E 149C 166.92 169.71 REMARK 500 ALA E 149D -124.67 -131.26 REMARK 500 VAL E 150 -69.02 112.04 REMARK 500 TYR E 204A -71.61 -77.44 REMARK 500 ASN E 205 36.52 -98.69 REMARK 500 SER E 214 -72.93 -100.16 REMARK 500 ASP E 221 31.71 71.67 REMARK 500 ARG E 244 76.24 40.46 REMARK 500 ALA J 1E -34.17 159.48 REMARK 500 GLU J 1C 26.32 -78.50 REMARK 500 ASP J 1A -20.80 -154.85 REMARK 500 PHE J 7 -83.21 -127.66 REMARK 500 PRO K 28 -5.13 -57.50 REMARK 500 SER K 36A 116.86 -165.81 REMARK 500 GLN K 38 -9.61 -57.05 REMARK 500 SER K 48 176.06 179.41 REMARK 500 TYR K 60A 82.45 -154.91 REMARK 500 ASN K 60G 77.36 -161.65 REMARK 500 HIS K 71 -49.86 -133.50 REMARK 500 GLU K 97A -60.01 -92.35 REMARK 500 ASN K 98 17.51 -145.82 REMARK 500 SER K 115 -157.19 -154.58 REMARK 500 TRP K 148 -166.49 -39.31 REMARK 500 THR K 149 -164.20 -58.48 REMARK 500 THR K 149A -17.85 -27.16 REMARK 500 ALA K 149D -136.19 39.36 REMARK 500 ASN K 205 44.04 -61.39 REMARK 500 SER K 214 -78.93 -117.62 REMARK 500 LEU K 245 95.46 111.36 REMARK 500 PHE M 1G -150.03 -146.53 REMARK 500 ALA M 1B -33.67 -31.34 REMARK 500 PHE M 7 -81.84 -127.16 REMARK 500 GLN M 14A -33.05 -36.96 REMARK 500 CYS N 42 -177.70 178.70 REMARK 500 SER N 48 -176.27 -174.08 REMARK 500 HIS N 57 -7.78 -59.05 REMARK 500 REMARK 500 THIS ENTRY HAS 67 RAMACHANDRAN OUTLIERS. REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 OPR F 16 PRO F 18 -94.05 REMARK 500 OPR G 16 PRO G 18 -93.75 REMARK 500 OPR I 16 PRO I 18 -93.55 REMARK 500 OPR I 16 PRO I 18 -93.20 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: MAIN CHAIN PLANARITY REMARK 500 REMARK 500 THE FOLLOWING RESIDUES HAVE A PSEUDO PLANARITY REMARK 500 TORSION ANGLE, C(I) - CA(I) - N(I+1) - O(I), GREATER REMARK 500 10.0 DEGREES. (M=MODEL NUMBER; RES=RESIDUE NAME; REMARK 500 C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 500 I=INSERTION CODE). REMARK 500 REMARK 500 M RES CSSEQI ANGLE REMARK 500 OPR F 16 64.44 REMARK 500 OPR G 16 39.12 REMARK 500 OPR I 16 59.36 REMARK 500 OPR I 16 58.96 REMARK 500 REMARK 500 REMARK: NULL REMARK 999 REMARK 999 SEQUENCE REMARK 999 CHYMOTRYPSINOGEN NUMBERING (RATHER THAN SEQUENTIAL) SYSTEM REMARK 999 IS USED, BASED ON THE TOPOLOGICAL ALIGNMENT WITH THE REMARK 999 STRUCTURE OF CHYMOTRYPSINOGEN (H.BRANDSTETTER ET AL., 1992, REMARK 999 J.MOL.BIOL., V. 226, 1085). THE N-TERMINUS OF THE REMARK 999 FIBRINOPEPTIDE IS ACETYLATED. FIBRINOPEPTIDE SEQUENCE REMARK 999 NUMBERS ARE ACE 6 TO ARG 19. A NEW RESIDUE, OPR, HAS BEEN REMARK 999 DEFINED FOR THE ARG/GLY COMBINATION IN WHICH THE AMIDE REMARK 999 NITROGEN HAS BEEN REPLACED WITH A CH2, MAKING THE NORMAL REMARK 999 AMIDE BOND BETWEEN THESE TWO RESIDUES A KETONE BOND. THE REMARK 999 FIBRINOPEPTIDE NUMBERING IS CONSEQUENTLY INCREMENTED BY REMARK 999 1 AFTER THIS RESIDUE IN KEEPING WITH THE FIBRINOGEN REMARK 999 NUMBERING SCHEME. THERE ARE ALTERNATE CONFORMATIONS FOR REMARK 999 RESIDUES PRO 18 AND ARG 19 IN FIBRINOPEPTIDE III. DBREF 1UCY L 1H 15 UNP P00735 THRB_BOVIN 318 366 DBREF 1UCY H 16 149A UNP P00735 THRB_BOVIN 367 516 DBREF 1UCY E 149B 247 UNP P00735 THRB_BOVIN 517 625 DBREF 1UCY F 6 16 UNP P12803 FIBA_MACFU 6 16 DBREF 1UCY J 1H 15 UNP P00735 THRB_BOVIN 318 366 DBREF 1UCY K 16 247 UNP P00735 THRB_BOVIN 367 625 DBREF 1UCY G 6 16 UNP P12803 FIBA_MACFU 6 16 DBREF 1UCY M 1H 15 UNP P00735 THRB_BOVIN 318 366 DBREF 1UCY N 16 247 UNP P00735 THRB_BOVIN 367 625 DBREF 1UCY I 6 16 UNP P12803 FIBA_MACFU 6 16 SEQADV 1UCY ACE F 6 UNP P12803 GLY 6 CONFLICT SEQADV 1UCY OPR F 16 UNP P12803 ARG 16 CONFLICT SEQADV 1UCY ACE G 6 UNP P12803 GLY 6 CONFLICT SEQADV 1UCY OPR G 16 UNP P12803 ARG 16 CONFLICT SEQADV 1UCY ACE I 6 UNP P12803 GLY 6 CONFLICT SEQADV 1UCY OPR I 16 UNP P12803 ARG 16 CONFLICT SEQRES 1 L 49 THR SER GLU ASP HIS PHE GLN PRO PHE PHE ASN GLU LYS SEQRES 2 L 49 THR PHE GLY ALA GLY GLU ALA ASP CYS GLY LEU ARG PRO SEQRES 3 L 49 LEU PHE GLU LYS LYS GLN VAL GLN ASP GLN THR GLU LYS SEQRES 4 L 49 GLU LEU PHE GLU SER TYR ILE GLU GLY ARG SEQRES 1 H 150 ILE VAL GLU GLY GLN ASP ALA GLU VAL GLY LEU SER PRO SEQRES 2 H 150 TRP GLN VAL MET LEU PHE ARG LYS SER PRO GLN GLU LEU SEQRES 3 H 150 LEU CYS GLY ALA SER LEU ILE SER ASP ARG TRP VAL LEU SEQRES 4 H 150 THR ALA ALA HIS CYS LEU LEU TYR PRO PRO TRP ASP LYS SEQRES 5 H 150 ASN PHE THR VAL ASP ASP LEU LEU VAL ARG ILE GLY LYS SEQRES 6 H 150 HIS SER ARG THR ARG TYR GLU ARG LYS VAL GLU LYS ILE SEQRES 7 H 150 SER MET LEU ASP LYS ILE TYR ILE HIS PRO ARG TYR ASN SEQRES 8 H 150 TRP LYS GLU ASN LEU ASP ARG ASP ILE ALA LEU LEU LYS SEQRES 9 H 150 LEU LYS ARG PRO ILE GLU LEU SER ASP TYR ILE HIS PRO SEQRES 10 H 150 VAL CYS LEU PRO ASP LYS GLN THR ALA ALA LYS LEU LEU SEQRES 11 H 150 HIS ALA GLY PHE LYS GLY ARG VAL THR GLY TRP GLY ASN SEQRES 12 H 150 ARG ARG GLU THR TRP THR THR SEQRES 1 E 109 SER VAL ALA GLU VAL GLN PRO SER VAL LEU GLN VAL VAL SEQRES 2 E 109 ASN LEU PRO LEU VAL GLU ARG PRO VAL CYS LYS ALA SER SEQRES 3 E 109 THR ARG ILE ARG ILE THR ASP ASN MET PHE CYS ALA GLY SEQRES 4 E 109 TYR LYS PRO GLY GLU GLY LYS ARG GLY ASP ALA CYS GLU SEQRES 5 E 109 GLY ASP SER GLY GLY PRO PHE VAL MET LYS SER PRO TYR SEQRES 6 E 109 ASN ASN ARG TRP TYR GLN MET GLY ILE VAL SER TRP GLY SEQRES 7 E 109 GLU GLY CYS ASP ARG ASP GLY LYS TYR GLY PHE TYR THR SEQRES 8 E 109 HIS VAL PHE ARG LEU LYS LYS TRP ILE GLN LYS VAL ILE SEQRES 9 E 109 ASP ARG LEU GLY SER SEQRES 1 F 13 ACE ASP PHE LEU ALA GLU GLY GLY GLY VAL OPR PRO ARG SEQRES 1 J 49 THR SER GLU ASP HIS PHE GLN PRO PHE PHE ASN GLU LYS SEQRES 2 J 49 THR PHE GLY ALA GLY GLU ALA ASP CYS GLY LEU ARG PRO SEQRES 3 J 49 LEU PHE GLU LYS LYS GLN VAL GLN ASP GLN THR GLU LYS SEQRES 4 J 49 GLU LEU PHE GLU SER TYR ILE GLU GLY ARG SEQRES 1 K 259 ILE VAL GLU GLY GLN ASP ALA GLU VAL GLY LEU SER PRO SEQRES 2 K 259 TRP GLN VAL MET LEU PHE ARG LYS SER PRO GLN GLU LEU SEQRES 3 K 259 LEU CYS GLY ALA SER LEU ILE SER ASP ARG TRP VAL LEU SEQRES 4 K 259 THR ALA ALA HIS CYS LEU LEU TYR PRO PRO TRP ASP LYS SEQRES 5 K 259 ASN PHE THR VAL ASP ASP LEU LEU VAL ARG ILE GLY LYS SEQRES 6 K 259 HIS SER ARG THR ARG TYR GLU ARG LYS VAL GLU LYS ILE SEQRES 7 K 259 SER MET LEU ASP LYS ILE TYR ILE HIS PRO ARG TYR ASN SEQRES 8 K 259 TRP LYS GLU ASN LEU ASP ARG ASP ILE ALA LEU LEU LYS SEQRES 9 K 259 LEU LYS ARG PRO ILE GLU LEU SER ASP TYR ILE HIS PRO SEQRES 10 K 259 VAL CYS LEU PRO ASP LYS GLN THR ALA ALA LYS LEU LEU SEQRES 11 K 259 HIS ALA GLY PHE LYS GLY ARG VAL THR GLY TRP GLY ASN SEQRES 12 K 259 ARG ARG GLU THR TRP THR THR SER VAL ALA GLU VAL GLN SEQRES 13 K 259 PRO SER VAL LEU GLN VAL VAL ASN LEU PRO LEU VAL GLU SEQRES 14 K 259 ARG PRO VAL CYS LYS ALA SER THR ARG ILE ARG ILE THR SEQRES 15 K 259 ASP ASN MET PHE CYS ALA GLY TYR LYS PRO GLY GLU GLY SEQRES 16 K 259 LYS ARG GLY ASP ALA CYS GLU GLY ASP SER GLY GLY PRO SEQRES 17 K 259 PHE VAL MET LYS SER PRO TYR ASN ASN ARG TRP TYR GLN SEQRES 18 K 259 MET GLY ILE VAL SER TRP GLY GLU GLY CYS ASP ARG ASP SEQRES 19 K 259 GLY LYS TYR GLY PHE TYR THR HIS VAL PHE ARG LEU LYS SEQRES 20 K 259 LYS TRP ILE GLN LYS VAL ILE ASP ARG LEU GLY SER SEQRES 1 G 13 ACE ASP PHE LEU ALA GLU GLY GLY GLY VAL OPR PRO ARG SEQRES 1 M 49 THR SER GLU ASP HIS PHE GLN PRO PHE PHE ASN GLU LYS SEQRES 2 M 49 THR PHE GLY ALA GLY GLU ALA ASP CYS GLY LEU ARG PRO SEQRES 3 M 49 LEU PHE GLU LYS LYS GLN VAL GLN ASP GLN THR GLU LYS SEQRES 4 M 49 GLU LEU PHE GLU SER TYR ILE GLU GLY ARG SEQRES 1 N 259 ILE VAL GLU GLY GLN ASP ALA GLU VAL GLY LEU SER PRO SEQRES 2 N 259 TRP GLN VAL MET LEU PHE ARG LYS SER PRO GLN GLU LEU SEQRES 3 N 259 LEU CYS GLY ALA SER LEU ILE SER ASP ARG TRP VAL LEU SEQRES 4 N 259 THR ALA ALA HIS CYS LEU LEU TYR PRO PRO TRP ASP LYS SEQRES 5 N 259 ASN PHE THR VAL ASP ASP LEU LEU VAL ARG ILE GLY LYS SEQRES 6 N 259 HIS SER ARG THR ARG TYR GLU ARG LYS VAL GLU LYS ILE SEQRES 7 N 259 SER MET LEU ASP LYS ILE TYR ILE HIS PRO ARG TYR ASN SEQRES 8 N 259 TRP LYS GLU ASN LEU ASP ARG ASP ILE ALA LEU LEU LYS SEQRES 9 N 259 LEU LYS ARG PRO ILE GLU LEU SER ASP TYR ILE HIS PRO SEQRES 10 N 259 VAL CYS LEU PRO ASP LYS GLN THR ALA ALA LYS LEU LEU SEQRES 11 N 259 HIS ALA GLY PHE LYS GLY ARG VAL THR GLY TRP GLY ASN SEQRES 12 N 259 ARG ARG GLU THR TRP THR THR SER VAL ALA GLU VAL GLN SEQRES 13 N 259 PRO SER VAL LEU GLN VAL VAL ASN LEU PRO LEU VAL GLU SEQRES 14 N 259 ARG PRO VAL CYS LYS ALA SER THR ARG ILE ARG ILE THR SEQRES 15 N 259 ASP ASN MET PHE CYS ALA GLY TYR LYS PRO GLY GLU GLY SEQRES 16 N 259 LYS ARG GLY ASP ALA CYS GLU GLY ASP SER GLY GLY PRO SEQRES 17 N 259 PHE VAL MET LYS SER PRO TYR ASN ASN ARG TRP TYR GLN SEQRES 18 N 259 MET GLY ILE VAL SER TRP GLY GLU GLY CYS ASP ARG ASP SEQRES 19 N 259 GLY LYS TYR GLY PHE TYR THR HIS VAL PHE ARG LEU LYS SEQRES 20 N 259 LYS TRP ILE GLN LYS VAL ILE ASP ARG LEU GLY SER SEQRES 1 I 13 ACE ASP PHE LEU ALA GLU GLY GLY GLY VAL OPR PRO ARG MODRES 1UCY OPR F 16 ARG C-(3-OXOPROPYL)ARGININE MODRES 1UCY OPR G 16 ARG C-(3-OXOPROPYL)ARGININE MODRES 1UCY OPR I 16 ARG C-(3-OXOPROPYL)ARGININE HET ACE F 6 3 HET OPR F 16 15 HET ACE G 6 3 HET OPR G 16 15 HET ACE I 6 3 HET OPR I 16 15 HETNAM ACE ACETYL GROUP HETNAM OPR (5S)-5-AMINO-8-CARBAMIMIDAMIDO-4-OXOOCTANOIC ACID FORMUL 4 ACE 3(C2 H4 O) FORMUL 4 OPR 3(C9 H18 N4 O3) FORMUL 11 HOH *733(H2 O) HELIX 1 1 GLU L 14C GLU L 14H 1 6 HELIX 2 2 ALA H 56 CYS H 58 5 3 HELIX 3 3 PRO H 60B TRP H 60D 5 3 HELIX 4 4 VAL H 61 ASP H 63 5 3 HELIX 5 5 LYS H 126 LEU H 129C 1 7 HELIX 6 6 ARG E 165 ALA E 170 1 6 HELIX 7 7 PRO E 186 GLU E 186B 5 3 HELIX 8 8 VAL E 231 ILE E 242 1 12 HELIX 9 9 LEU F 9 GLU F 11 5 3 HELIX 10 10 GLU J 8 LYS J 10 5 3 HELIX 11 11 GLU J 14C GLU J 14L 1 10 HELIX 12 12 ALA K 56 CYS K 58 5 3 HELIX 13 13 PRO K 60B TRP K 60D 5 3 HELIX 14 14 VAL K 61 ASP K 63 5 3 HELIX 15 15 LYS K 126 LEU K 129C 1 7 HELIX 16 16 THR K 149A VAL K 149C 5 3 HELIX 17 17 ARG K 165 SER K 171 1 7 HELIX 18 18 VAL K 231 ILE K 242 5 12 HELIX 19 19 GLY M 1F GLY M 1D 5 3 HELIX 20 20 GLU M 14C ILE M 14K 1 9 HELIX 21 21 ALA N 56 CYS N 58 5 3 HELIX 22 22 PRO N 60B TRP N 60D 5 3 HELIX 23 23 LYS N 126 LEU N 129C 1 7 HELIX 24 24 ARG N 165 SER N 171 1 7 HELIX 25 25 LYS N 235 ILE N 242 1 8 SHEET 1 A 4 LYS H 81 MET H 84 0 SHEET 2 A 4 LEU H 64 ILE H 68 -1 N ILE H 68 O LYS H 81 SHEET 3 A 4 GLN H 30 ARG H 35 -1 N PHE H 34 O LEU H 65 SHEET 4 A 4 GLU H 39 SER H 45 -1 N ALA H 44 O VAL H 31 SHEET 1 B 3 TRP H 51 THR H 54 0 SHEET 2 B 3 ALA H 104 LEU H 108 -1 N LEU H 106 O VAL H 52 SHEET 3 B 3 LEU H 85 ILE H 90 -1 N TYR H 89 O LEU H 105 SHEET 1 C 2 LYS H 135 GLY H 140 0 SHEET 2 C 2 GLN E 156 PRO E 161 -1 N LEU E 160 O GLY H 136 SHEET 1 D 4 MET E 180 ALA E 183 0 SHEET 2 D 4 GLY E 226 HIS E 230 -1 N TYR E 228 O PHE E 181 SHEET 3 D 4 TRP E 207 TRP E 215 -1 N TRP E 215 O PHE E 227 SHEET 4 D 4 PRO E 198 LYS E 202 -1 N MET E 201 O TYR E 208 SHEET 1 E 4 LYS K 81 MET K 84 0 SHEET 2 E 4 LEU K 64 ILE K 68 -1 N ILE K 68 O LYS K 81 SHEET 3 E 4 GLN K 30 ARG K 35 -1 N PHE K 34 O LEU K 65 SHEET 4 E 4 LEU K 40 SER K 45 -1 N ALA K 44 O VAL K 31 SHEET 1 F 3 TRP K 51 THR K 54 0 SHEET 2 F 3 ALA K 104 LEU K 108 -1 N LEU K 106 O VAL K 52 SHEET 3 F 3 LEU K 85 ILE K 90 -1 N TYR K 89 O LEU K 105 SHEET 1 G 2 LYS K 135 GLY K 140 0 SHEET 2 G 2 GLN K 156 PRO K 161 -1 N LEU K 160 O GLY K 136 SHEET 1 H 4 MET K 180 ALA K 183 0 SHEET 2 H 4 GLY K 226 HIS K 230 -1 N TYR K 228 O PHE K 181 SHEET 3 H 4 TRP K 207 TRP K 215 -1 N TRP K 215 O PHE K 227 SHEET 4 H 4 PRO K 198 LYS K 202 -1 N MET K 201 O TYR K 208 SHEET 1 I 4 LYS N 81 MET N 84 0 SHEET 2 I 4 LEU N 64 ILE N 68 -1 N ILE N 68 O LYS N 81 SHEET 3 I 4 GLN N 30 ARG N 35 -1 N PHE N 34 O LEU N 65 SHEET 4 I 4 GLU N 39 SER N 45 -1 N ALA N 44 O VAL N 31 SHEET 1 J 3 TRP N 51 THR N 54 0 SHEET 2 J 3 ALA N 104 LEU N 108 -1 N LEU N 106 O VAL N 52 SHEET 3 J 3 LEU N 85 ILE N 90 -1 N TYR N 89 O LEU N 105 SHEET 1 K 2 LYS N 135 GLY N 140 0 SHEET 2 K 2 GLN N 156 PRO N 161 -1 N LEU N 160 O GLY N 136 SHEET 1 L 4 MET N 180 ALA N 183 0 SHEET 2 L 4 GLY N 226 HIS N 230 -1 N TYR N 228 O PHE N 181 SHEET 3 L 4 TRP N 207 TRP N 215 -1 N TRP N 215 O PHE N 227 SHEET 4 L 4 PRO N 198 LYS N 202 -1 N MET N 201 O TYR N 208 SSBOND 1 CYS L 1 CYS H 122 1555 1555 2.03 SSBOND 2 CYS H 42 CYS H 58 1555 1555 2.01 SSBOND 3 CYS E 168 CYS E 182 1555 1555 2.02 SSBOND 4 CYS E 191 CYS E 220 1555 1555 2.03 SSBOND 5 CYS J 1 CYS K 122 1555 1555 2.01 SSBOND 6 CYS K 42 CYS K 58 1555 1555 2.02 SSBOND 7 CYS K 168 CYS K 182 1555 1555 2.02 SSBOND 8 CYS K 191 CYS K 220 1555 1555 2.03 SSBOND 9 CYS M 1 CYS N 122 1555 1555 2.03 SSBOND 10 CYS N 42 CYS N 58 1555 1555 2.02 SSBOND 11 CYS N 168 CYS N 182 1555 1555 2.04 SSBOND 12 CYS N 191 CYS N 220 1555 1555 2.03 LINK C ACE F 6 N ASP F 7 1555 1555 1.33 LINK C VAL F 15 N OPR F 16 1555 1555 1.33 LINK C OPR F 16 N PRO F 18 1555 1555 1.34 LINK C ACE G 6 N ASP G 7 1555 1555 1.33 LINK C VAL G 15 N OPR G 16 1555 1555 1.32 LINK C OPR G 16 N PRO G 18 1555 1555 1.34 LINK C ACE I 6 N ASP I 7 1555 1555 1.33 LINK C VAL I 15 N OPR I 16 1555 1555 1.33 LINK C OPR I 16 N APRO I 18 1555 1555 1.33 LINK C OPR I 16 N BPRO I 18 1555 1555 1.33 CISPEP 1 SER H 36A PRO H 37 0 -1.42 CISPEP 2 SER K 36A PRO K 37 0 -0.19 CISPEP 3 SER N 36A PRO N 37 0 0.67 CRYST1 82.470 88.780 98.550 90.00 106.21 90.00 P 1 21 1 6 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.012126 0.000000 0.003525 0.00000 SCALE2 0.000000 0.011264 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010567 0.00000